Innovative strategy in treating angina pectoris with Chinese patent medicines by promoting blood circulation and removing blood stasis: Experience from combination therapy in chinese medicine

Current Vascular Pharmacology

Volumn 13, Issue 4, 2015, Pages 540-553

  Xiong, Xing Jiang ^a   Wang, Zhong ^a   Wang, Jie ^a  

^a INSTITUTE OF CHINESE MATERIA MEDICA   (China)

Author keywords

Angina pectoris; Chinese patent medicine (CPM); Combination therapy; Promoting blood circulation and removing blood stasis (PBCRBS)

Indexed keywords

CHINESE DRUG; CHOLESTEROL; DANSHEN DRIPPING; ISOSORBIDE DINITRATE; SUXIAO JIUXIN; TONG XIN LUO CAPSULE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; XUEFU ZHUYU CAPSULE; BIOLOGICAL MARKER; CARDIOVASCULAR AGENT; HERBACEOUS AGENT;

ANGINA PECTORIS; ARTICLE; BLOOD STASIS SYNDROME; CHINESE MEDICINE; CIRCULATION; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DIZZINESS; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRY THROAT; DYSPEPSIA; ECONOMIC ASPECT; ELECTROCARDIOGRAPHY; EPIGASTRIC DISCOMFORT; FAINTNESS; HEADACHE; HEMATOLOGICAL PARAMETERS; HUMAN; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; META ANALYSIS (TOPIC); NAUSEA; PATENT; PROMOTING BLOOD CIRCULATION AND REMOVING BLOOD STASIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SKIN REDNESS; STOMACH PAIN; UNSTABLE ANGINA PECTORIS; VASCULAR DISEASE; WESTERN MEDICINE; BLOOD; BLOOD CLOTTING; COMBINATION DRUG THERAPY; DRUG EFFECTS; PATHOPHYSIOLOGY; PROCEDURES; TREATMENT OUTCOME;

ANGINA PECTORIS; BIOMARKERS; BLOOD CIRCULATION; BLOOD COAGULATION; CARDIOVASCULAR AGENTS; DRUG THERAPY, COMBINATION; DRUGS, CHINESE HERBAL; HUMANS; MEDICINE, CHINESE TRADITIONAL; TREATMENT OUTCOME;

EID: 84938684638     PISSN: 15701611     EISSN: 18756212     Source Type: Journal    
DOI: 10.2174/1570161112666141014153735     Document Type: Article

References (188)

1. Yach D, Hawkes C, Gould CL, Hofman KJ. The global burden of chronic diseases: overcoming impediments to prevention and control. JAMA 2004; 291: 2616-22.
2. Braunwald E. The rise of cardiovascular medicine. Eur Heart J 2012; 33: 838-45.
3. Jr SC. Cardiovascular community and the United Nations reducing the global burden of ischemic heart disease and stroke: a challenge for the cardiovascular community and the United Nations. Circulation 2011; 124: 278-9.
4. Anand SS, Yusuf S. Stemming the global tsunami of cardiovascular disease. Lancet 2011; 377: 529-32.
5. Fraker Jr TD, Fihn SD, writing on behalf of the 2002 Chronic Stable Angina Writing Committee. 2007 Chronic Angina Focused Update of the ACC/AHA 2002 Guidelines for the Management of Patients With Chronic Stable Angina: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Writing Group to Develop the Focused Update of the 2002 Guidelines for the Management of Patients With Chronic Stable Angina. Circulation 2007; 116: 2762-72.
6. Anderson JL, Adams CD, Antman EM, et al. 2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-STElevation Myocardial Infarction: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011; 123: e426-579.
7. Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF/AHA/ ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: Executive Summary: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,and the American College of Physicians,American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 2012; 126: 3097-137.
8. Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF/AHA/ ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 2012; 126: e354-471.
9. Chen KJ, Hui KK, Lee MS, Xu H. The potential benefit of complementary/ alternative medicine in cardiovascular diseases. Evid Based Complement Alternat Med2012; 2012: Article ID 125029.
10. Su DJ, Li LF. Trends in the use of complementary and alternative medicine in the United States: 2002-2007. J Health Care for the Poor and Underserved 2011; 22: 295-309.
11. Lauche R, Cramer H, Moebus S, et al. Results of a 2-week inpatient stay at the department for internal and integrative medicine: an observational study. Evid Based Complement Alternat Med 2012; 2012: Article ID 875874.
12. Hawk C, Ndetan H, Evans MW. Potential role of complementary and alternative health care providers in chronic disease prevention and health promotion: an analysis of National Health Interview Survey data. Prevent Med 2012; 54: 18-22.
13. Yeh GY, Davis RB, Phillips RS. Use of complementary therapies in patients with cardiovascular disease. Am J Cardiol 2006; 98: 673-80.
14. Xu H and Chen KJ, Complementary and alternative medicine: is it possible to be mainstream? Chin J Integr Med 2012; 18: 403-4.
15. Chen KJ. Where are we going? Chin J Integr Med 2010; 16: 100-1.
16. Xiong XJ, Chu FY, Li HX, He QY. Clinical application of the TCM classic formulae for treating chronic bronchitis. J Trad Chin Med 2011; 31: 69-72.
17. Suen LK, Lau YK, Ma HC, Lai KW, Holroyd E. Predictive value of auricular diagnosis on coronary heart disease. Evid Based Complement Alternat Med 2012; 2012: Article ID 706249.
18. Chen KJ, Xu H. The integration of traditional Chinese medicine and western medicine. Europ Rev 2003; 11: 225-35.
19. Chen KJ, Li LZ. Study of traditional Chinese medicine--which is after all the right way? Chin J Integr Med 2005; 11: 241-2.
20. Wang J, Xiong XJ, Current situation and perspectives of clinical study in integrative medicine in China. Evid Based Complement Alternat Med 2012; 2012: Article ID 268542.
21. Xu H, Chen KJ. Integrative medicine: the experience from China. J Altern Complement Med 2008; 14: 3-7.
22. Dobos G, Tao I. The model of western integrative medicine: the role of Chinese medicine. Chin J Integr Med 2011; 17: 11-20.
23. Liu MY, Chen KJ. Convergence: the tradition and the modern. Chin J Integr Med 2012; 18: 164-5.
24. Xu FQ, Chen KJ, Ma XC, et al. Clinical observation on effect of xiongshao capsule on coronary heart disease with angina pectoris. Zhongguo Zhong Xi Yi Jie He Za Zhi 2003; 23: 16-8.
25. Peng W, Shi DZ, Xue YT, Gao HC, Zhang FR. Effect of Xiongshao capsule in treating 112 patients with coronary heart disease angina pectoris of Xin-blood stasis syndrome. Zhongguo Zhong Xi Yi Jie He Za Zhi 2011; 31: 191-4.
26. Shang QH, Xu H, Lu XY, Wen C, Shi DZ, Chen KJ. A multicenter randomized double-blind placebo-controlled trial of Xiongshao Capsule in preventing restenosis after percutaneous coronary intervention: a subgroup analysis of senile patients. Chin J Integr Med 2011; 17: 669-74.
27. Gao ZY, Xu H, Shi DZ, Wen C, Liu BY. Analysis on outcome of 5284 patients with coronary artery disease: the role of integrative medicine. J Ethnopharmacol 2011; doi:10.1016/j.jep.2011.08.071.
28. Chen KJ, Shi DZ, Xu H, et al. XS0601 reduces the incidence of restenosis:a prospective study of 335 patients undergoing percutaneous coronary intervention in China. Chin Med J 2006; 119: 6-13.
29. Zhang Q, Liu AD, Huang YS. Clinical non-inferiority trial on treatment of coronary heart disease angina pectoris of xin-blood stasis syndrome type with lyophilized salvia salt of lithospermic acid powder for injection. Chin J Integr Med 2006; 12: 12-8.
30. Zhang Q, Peng JH, Zhang XN. A clinical study of Safflower Yellow injection in treating coronary heart disease angina pectoris with xin-blood stagnation syndrome. Chin J Integr Med 2005; 11: 222-5.
31. Li DZ, Sharma R, Zeng QZ. Effects of Ginkgo Leaf Extract on function of dendritic cells and Th1/Th2 cytokines in patients with unstable angina pectoris. Chin J Integr Med 2005; 11: 260-3.
32. Chen XL, Zhang JN, Yuan J, Yang B, Jiang L, Liu CY. Comparative study on the effects of small dose of aspirin combined with Ginkgo-damole injection and the effects of conventional dose of aspirin in treating senile unstable angina pectoris. Chin J Integr Med 2004; 10: 249-53.
33. Ma LH, Ruan YM, Jiao Z, Li XH. Effect of Chinese herbs for activating blood circulation, removing stasis and supplementing qi on the circulating endothelial cells in patients with unstable angina pectoris. Chin J Integr Med 2004; 10: 267-70.
34. Wang Y, Liu ZY, Li C, et al. Drug target prediction based on the herbs components: the study on the multitargets pharmacological mechanism of Qishenkeli acting on the coronary heart disease. Evid Based Complement Alternat Med 2012; 2012: Article ID 698531.
35. Li X, Xu X, Wang J, et al. A system-level investigation into the mechanisms of Chinese traditional medicine: compound Danshen formula for cardiovascular disease treatment. PLoS One 2012; 7: e43918.
36. Li JJ, Hu SS, Fang CH, et al. Effects of Xuezhikang,an extract of cholestin,on lipid profile and C-reactive protein:a short-term time course study in patients with stable angina. Clinica Chimica Acta 2005; 352: 217-24.
37. Shang QH, Xu H, Huang L. Tanshinone IIA. A promising natural cardioprotective agent. Evid Based Complement Alternat Med 2012; 2012: Article ID 716459.
38. Shang JJ, Shi H, Zhou Q, Gao W, Liu HX. A study of prognosis, outcome, and changing tendency of hospitalized AMI patients in Beijing third-grade a-level traditional Chinese medicine hospitals from 1999 to 2008. Evid Based Complement Alternat Med2012; 2012: Article ID 837194.
39. Wang J, Xiong XJ. Control strategy on hypertension in Chinese medicine. Evid Based Complement Alternat Med 2012; 2012: Article ID 284847.
40. Xiong XJ, Wang J. Discussion of related problems in herbal prescription science based on objective indications of herbs. J Chin Integr Med 2010; 8: 20-4.
41. Davidson P, Hancock K, Leung D, et al. Traditional Chinese medicine and heart disease: what does western medicine and nursing science know about it? Eur J Cardiovasc Nurs 2003; 2: 171-81.
42. Sung AY, Rabe J, Ruan KH. Potentially beneficial herbal medicine for heart and cardiovascular diseases. Am J Integr Med 2011; 1: 14-23.
43. Chen JX, Lu P, Zuo XH, et al. Clinical data mining of phenotypic network in angina pectoris of coronary heart disease. Evid Based Complement Alternat Med 2012; 2012: Article ID 546230.
44. Wang J, Wang PQ, Xiong XJ. Current situation and reunderstanding of syndrome and formula syndrome in Chinese medicine. Intern Med 2012; 2: Article ID 1000113, 1-5.
45. Xiong XJ, Wang J. Experience of diagnosis and treatment of exogenous high-grade fever. J Chin Integr Med 2011; 9: 681-7.
46. Xiong XJ, Yang XC, Liu W, Chu FY, Wang PQ, Wang J. Trends in the treatment of hypertension from the perspective of traditional Chinese medicine. Evid Based Complement Alternat Med 2013; 2013: Article ID 275279.
47. Xiong XJ, Yang XC, Liu YM, Zhang Y, Wang PQ, Wang J. Chinese herbal formulas for treating hypertension in traditional Chinese medicine: perspective of modern science. Hypertension Res 2013; 36, 570-9.
48. Zhou JX, Tang M, Li J, Nie YY, Wang XG. Analysis of Chinese syndrome features and combination laws of 2029 patients with coronary heart disease angina. Zhongguo Zhong Xi Yi Jie He Za Zhi 2011; 31: 753-5.
49. Fang YT, Wang SR. An investigation on clinical studies of TCM in preventing and treating angina pectoris of coronary heart disease. Zhongguo Zhong Xi Yi Jie He Za Zhi 2003; 23: 338-40.
50. Ren Y, Zhang MZ, Chen KJ, et al. Clinical and epidemiological investigation of TCM syndromes of patients with coronary heart disease in China. Evid Based Complement Alternat Med 2012; 2012: Article ID 714517.
51. Zhao HH, Chen JX, Hou N, et al. Discovery of diagnosis pattern of coronary heart disease with qi deficiency syndrome by the T-Testbased adaboost algorithm. Evid Based Complement Alternat Med 2011; 2011: Article ID 408650.
52. Wang J, Chu FY, Li J, et al. Study on syndrome element characteristics and its correlation with coronary angiography in 324 patients with coronary heart disease. Chin J Integr Med 2008; 14: 274-80.
53. Chen KJ. Exploration on the possibility of reducing cardiovascular risk by treatment with Chinese medicine recipes for promoting blood-circulation and relieving blood-stasis. Zhongguo Zhong Xi Yi Jie He Za Zhi 2008; 28: 389.
54. Wang J, Li J, Yao KW, Zhong JB. Study on syndrome elements and their combination laws in patients with angina pectoris. Zhong Yi Za Zhi 2007; 48: 920-2.
55. Xiong XJ, Wang J. Explaining syndromes of decoction for removing blood stasis in chest. Zhongguo Zhong Yao Za Zhi 2011; 36: 3026-31.
56. Song MX, Yang M. Newly edited national Chinese traditional patent medicines. People's Health Publishing House 2002, 1234-5.
57. Gao Y. Reasonable application manual of traditional Chinese patent medicine in internal medicine. People's Health Publishing House 2009, 405.
58. Chu FY, Wang J, Yao KW, Li ZZ. Effect of Xuefu Zhuyu Capsule on the symptoms and signs and health-related quality of life in the unstable angina patients with blood-stasis syndrome after percutaneous coronary intervention: a randomized controlled trial. Chin J Integr Med 2010; 16: 399-405.
59. Zhao SP, Lu ZL, Du BM, et al. Xuezhikang, An extract of cholestin, reduces cardiovascular events in Type 2 diabetes patients with coronary heart disease: subgroup analysis of patients with Type 2 diabetes from China Coronary Secondary Prevention Study (CCSPS). J Cardiovasc Pharmacol 2007; 49: 81-4.
60. Li XK, Jing L, Lu P, et al. Efficacy of a Chinese herbal formula in patients with stable angina pectoris based on doctor and patient reported outcomes. Afr J Pharmacy Pharmacol 2012; 6: 1799-804.
61. Yan SY, Yao C, Ding XR, Jiang M, Lu AP. Serum low-density lipoprotein and heart rate related to the effectiveness in the treatment of angina pectoris with two similar Chinese medicine herbal formulae. Chin J Integr Med 2011; 17: 903-7.
62. Jin L. Effect of composite salvia dropping pill on function of platelet activation in patients with unstable angina pectoris. Zhongguo Zhong Xi Yi Jie He Za Zhi 2000; 20: 415-7.
63. Qiu ZX, Ma HJ, Wang DF. Observation on effect of compound Danshen droplet-pill combined with trimetazidine in treating senile unstable angina pectori. Zhongguo Zhong Xi Yi Jie He Za Zhi 2005; 25: 787-9.
64. Wang LJ, Luo XP, Wang Y, et al. Evaluation on tolerability and safety of long-term administration with Shexiang Baoxin pill in patients with coronary heart disease of stable angina pector. Zhongguo Zhong Xi Yi Jie He Za Zhi 2008; 28: 399-401.
65. Wang BX, Dong XM, Guo AM, Zhang J. Effects of Xuefu Zhuyu Decoction on functions of vascular endothelium in patients with unstable angina pectoris. Zhongguo Zhong Xi Yi Jie He Za Zhi 2006; 4: 256-9.
66. Zhuo Q, Yuan Z, Chen H, Wu T. Traditional Chinese herbal products for stable angina. Cochrane Database of Systematic Reviews 2010, Issue 5. Art. No.: CD004468. DOI: 10.1002/14651858. CD004468.pub2.
67. Li X, Xu X, Wang J, et al. A system-level investigation into the mechanisms of Chinese traditional medicine: compound Danshen formula for cardiovascular disease treatment. PLoS One 2012; 7: e43918.
68. Jia YL, Chen C, Ng CS, Leung SW. Meta-analysis of randomized controlled trials on the efficacy of Di'ao Xinxuekang capsule and isosorbide dinitrate in treating angina pectoris. Evid Based Complement Alternat Med vol. 2012, Article ID 904147, 8 pages, 2012.
69. Wang Q, Wu T, Chen X, et al. Puerarin injection for unstable angina pectoris. Cochrane Database Syst Rev 2006; 3: Art. No.: CD004196. DOI: 10.1002/14651858.CD004196.pub2.
70. Shang QH, Liu ZL, Chen KJ, Xu H, Liu JP. A systematic review of Xuezhikang, an extract from red yeast rice, for coronary heart disease complicated by dyslipidemia. Evid Based Complement Alternat Med 2012; 2012: Article ID 636547.
71. Qiu XL, Miles A, Jiang XH, Sun X, Yang N. Sulfotanshinone sodium injection for unstable angina pectoris: a systematic review of randomized controlled trials. Evid Based Complement Alternat Med 2012; 2012: Article ID 715790.
72. Hao CH, Zhang JY. Meta-analysis of Tongxinluo capsule for coronary heart disease angina. Zhongguo Xian Dai Yi Sheng 2010; 48: 6-9.
73. Lu AP, Chen KJ. Chinese medicine pattern diagnosis could lead to innovation in medical sciences. Chin J Integr Med 2011; 17: 811- 17.
74. Xu H, Chen KJ. Integrating traditional medicine with biomedicine towards a patient-centered healthcare system. Chin J Integr Med 2011; 17: 83-4.
75. Cheng TO. Cardiovascular effects of danshen. Int J Cardiol 2007; 14: 9-22.
76. Liao H, Banbury LK, Leach DN. Antioxidant activity of 45 Chinese herbs and the relationship with their TCM characteristics. Evid Based Complement Alternat Med 2008; 5: 429-34.
77. Liu Y, Yin HJ, Shi DZ, Chen KJ. Chinese herb and formulas for promoting blood circulation and removing blood stasis and antiplatelet therapies. Evid Based Complement Alternat Med 2012; 2012: Article ID 184503.
78. Meng J. Tasly Pharmaceuticals: The leader of modern traditional Chinese medicine. China Pharm 2007; 18: 239-40.
79. Su QH. Tasly Pharmaceuticals: focusing on word of mouth marketing. Contemp Manager 2009; 8: 96-7.
80. Xu H, Chen KJ. Making evidence-based decisions in the clinical practice of integrative medicine. Chin J Integr Med 2010; 16: 483- 5.
81. The Cochrane Collaboration. Cochrane reviews. 2011. http: //www.cochrane.org/cochrane-reviews/.
82. Wang J, Xiong XJ. Outcome measures of Chinese herbal medicine for hypertension: an overview of systematic reviews. Evid Based Complement Alternat Med 2012; 2012: Article ID 697237.
83. Medical Research Library of Brooklyn. The evidence pyramid. http://library.downstate.edu/EBM2/2100.htm.
84. Jia YL, Bao FF, Huang FY, Leung SW. Is Tongxinluo more effective than isosorbide dinitrate in treating angina pectoris? a systematic review and meta-analysis of randomized controlled trials. J Alternat Complement Med 2011; 17: 1109-17.
85. Wu T, Harrison RA, Chen X, et al. Tongxinluo (Tong xin luo or Tong-xin-luo) capsule for unstable angina pectoris. Cochrane Database Syst Rev 2006; 4: Art. No.: CD004474. DOI: 10.1002/14651858. CD004474. pub2.
86. Zhou ZR, Tang HX, Li JH, Yang LL, Hu H. Tongxinluo capsule for coronary heart disease: a systematic review. Zhongguo Xun Zheng Yi Xue Za Zhi 2011; 11: 1078-83.
87. Wang Y, Kuang YX. Meta-analysis of effect of Tongxinluo capsule on coronary heart disease angina. Xian Dai Zhong Xi Yi Jie He Za Zhi 2012; 21: 801-3, 866.
88. Xu GL, Lin SM, Qin L. Systematic review of Tongxinluo capsule on effectiveness and safety of elderly patients with unstable angina. Zhongguo Zhong Yi Ji Zheng 2012; 21: 409-10.
89. He HZ, Wu WK, Deng ZS, Ou SY, Liu SF, Zeng BL. Systematic review on randomized controlled trials for treatment of coronary heart disease by Tongxinluo capsule. Zhong Shan Da Xue Xue Bao 2007; 28: 573-7.
90. Cui HJ, He HY, Xing ZH. System evaluation and meta analysis of Xue fu zhu yu decoction on unstable angina pectoris. Zhongguo Zhong Yi Ji Zheng 2011; 20: 1071-74.
91. Zheng GH, Chen HY, Chu JF, Liu JP. Systematic review of randomize controlled trials on Xue fu zhu yu capsule for angina pectoris in patients with coronary heart disease. Zhong Yi Za Zhi 2012; 53: 117-21.
92. Zhang JH, Shang HC, Gao XM, et al. Compound salvia droplet pill, a traditional Chinese medicine, for the treatment of unstable angina pectoris: a systematic review. Med Sci Monit 2008; 14: RA 1-7.
93. Wang G, Wang L, Xiong ZY, Mao B, Li TQ. Compound salvia pellet, a traditional Chinese medicine, for the treatment of chronic stable angina pectoris compared with nitrates: a meta-analysis. Med Sci Monit 2006; 12: SR 1-7.
94. Jia YL, Huang FY, Zhang SK, Leung SW. Is danshen (Salvia miltiorrhiza) dripping pill more effective than isosorbide dinitrate in treating angina pectoris? a systematic review of randomized controlled trials. Int J Cardiol 2012; 157(3): 330-40.
95. Wang L, Xiong ZY, Wang G, Li TQ. Systematic assessment on randomized controlled trials for treatment of stable angina pectoris by compound salvia pellet. Zhongguo Zhong Xi Yi Jie He Za Zhi 2004; 24: 500-4.
96. Zhang MZ, Zhang J. Meta-analysis of compound salvia pellet on coronary heart disease. Shi Zhen Guo Yi Guo Yao 2009; 20: 1007- 8.
97. Jiang SY, Tong JC, Sun RY, Xie HT. Meta-analysis of compound Danshen dropping pills (DSP) in treating coronary heart disease angina. Shi Yong Yao Wu Yu Lin Chuang 2007; 10: 334-7.
98. Zhang MZ, Wang L, Chen BY, Nie GN. Meta-analysis of document on compound Danshen dropping pills (DSP) in treatment of patients with stable angina. Zhong Xi Yi Jie He Xin Nao Xue Guan Bing Za Zhi 2004; 2: 311-14.
99. Fan T, Wang G, Wang L, Xiong ZY, Mao B. Quality assessment of clinical studies on compound salvia pellet (CSP) for angina pectoris. Zhongguo Xun Zheng Yi Xue Za Zhi 2007; 7: 461-71.
100. Guo YM, Zhang C, Zha QL, Chen WN, Jiang M, Lv AP. Compound salvia droplet pill for treatment of coronary heart disease: a systematic review. Shanghai Zhong Yi Yao Da Xue Xue Bao 2012; 26: 24-31.
101. Guo ML, Zhao TT, Li JT. Meta-analysis of randomized controlled trials on compound danshen dropping pills compared with other three common drugs in treatment of acute angina. Xi Bu Yi Xue 2012; 24: 486-90.
102. Duan X, Zhou L, Wu T, et al. Chinese herbal medicine su xiao jiu xin wan for angina pectoris. Cochrane Database Syst Rev 2008; 1: Art. No.: CD004473. DOI: 10.1002/14651858. CD004473. pub2.
103. Wang XJ, Xu BN. Meta-analysis of su xiao jiu xin pill for angina pectoris. Shanxi Zhong Yi 2008; 29: 1249-1251.
104. Mehta S and Yusuf S. The clopidogrel in unstable angina to prevent recurrent events (CURE) trial programme: rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease. European Heart Journal 2000; 21: 2033-41.
105. Wang L, Zhang MZ, Guo LH, et al. Clinical pathways based on integrative medicine in Chinese hospitals improve treatment outcomes for patients with acute myocardial infarction: a multicentre, nonrandomized historically controlled trial. Evid Based Complement Alternat Med 2012; 2012: Article ID 821641.
106. Chung VH, Chen M, Ying Q, et al. Add-on effect of Chinese herbal medicine on mortality in myocardial infarction: systematic review and meta-analysis of randomized controlled trials. Evid Based Complement Alternat Med 2013; 2013: Article ID 675906.
107. Snow V, Barry P, Fihn SD, et al. Evaluation of primary care patients with chronic stable angina: guidelines from the American College of Physicians. Ann Intern Med 2004; 141: 57-64.
108. Abrams J. Chronic stable angina. N Engl J Med 2005; 352: 2524- 33.
109. Wei JF, Wu TX, Yang Q, Chen M, Ni J, Huang DJ. Nitrates for stable angina: a systematic review and meta-analysis of randomized clinical trials. Int J Cardiol 2011; 146: 4-12.
110. Wang ZG, Ren J. Current status and future direction of Chinese herbal medicine. Trends Pharmacol Sci 2002; 23: 347-8.
111. Normile D. Asian medicine: the new face of traditional Chinese medicine. Science 2003; 299: 188-90.
112. Chen KJ. Clinical service of Chinese medicine. Chin J Integr Med 2008; 14: 163-4.
113. Chu FY, Wang J, Sun XW, et al. A randomized double-blinded controlled trial of Xuefu Zhuyu Capsule on short-term quality of life in unstable anginal patients with blood-stasis syndrome after percutaneous coronary intervention. J Chin Integr Med 2009; 7: 729-35.
114. Wang J, Yao KW, Yang XC, et al. Chinese patent medicine liu wei di huang wan combined with antihypertensive drugs, a new integrative medicine therapy, for the treatment of essential hypertension: a systematic review of randomized controlled trials. Evid Based Complement Alternat Med 2012; 2012: Article ID 714805.
115. Xiong XJ, Yang XC, Liu W, et al. Banxia baizhu tianma decoction for essential hypertension: a systematic review of randomized controlled trials. Evid Based Complement Alternat Med 2012; 2012: Article ID 271462.
116. Chan K. Some aspects of toxic contaminants in herbal medicines. Chemosphere 2003; 52: 1361-71.
117. Yang L, Su T, Li XM, et al. Aristolochic acid nephropathy: variation in presentation and prognosis. Nephrol Dial Transplant 2012; 27: 292-8.
118. Wang JS, Heijden R, Spruit S, et al. Quality and safety of Chinese herbal medicines guided by a systems biology perspective. J Ethnopharmacol 2009; 126: 31-41.
119. Shen ZY, Chen X. Analysis on 99 cases of adverse reactions of Chinese patent drugs. Afr J Microbiol Res 2012; 6: 1742-6.
120. Xiong XJ, Wang J, He QY. Thinking about reducing adverse reactions based on idea of formula corresponding to syndromes. Zhongguo Zhong Yao Za Zhi 2010; 35: 536-8.
121. Wang J, Xiong XJ. Evidence-based Chinese Medicine for Hypertension [J]. Evid Based Complement Alternat Med 2013; 2013: Article ID 978398, 1-12.
122. Xu H, Chen KJ. Herb-drug interaction: an emerging issue of integrative medicine. Chin J Integr Med 2010; 16: 195-6.
123. Miller LG. Herbal medicinal: selected clinical considerations focusing on known or potential drug-herb interactions. Arch Intern Med 1998; 158: 2200-11.
124. Tachjian A, Maria V, Jahangir A. Use of herbal products and potential interactions in patients with cardiovascular diseases. J Am Coll Cardiol 2010; 55: 515-25.
125. Adriane FB. Herb-drug interactions. Lancet 2000; 355: 134-38.
126. Xu H, Chen KJ. Difficulties and countermeasures in research for prevention and treatment of coronary heart disease by integrative Chinese and western medicine. Zhongguo Zhong Xi Yi Jie He Za Zhi 2007; 27: 647-649.
127. Liu YF, Yu HM, Zhang C, et al. Effects of Quyu Xiaoban Capsules on clinical outcomes and platelet activation and aggregation in patients with unstable angina pectoris. J Altern Complement Med 2007; 13: 369-374.
128. Pan SY, Chen SB, Dong HG, et al. New perspectives on Chinese herbal medicine (Zhong-Yao) research and development. Evid Based Complement Alternat Med 2011; 2011: Article ID 403709.
129. Chen KJ. Blood stasis syndrome and its treatment with activating blood circulation to remove blood stasis therapy. Chin J Integr Med 2012; 18: 891-6.
130. Feng Y, Xu H, Chen KJ. Natural polypill xuezhikang: its clinical benefit and potential multicomponent synergistic mechanisms of action in cardiovascular disease and other chronic conditions. J Altern Complement Med 2012; 18: 318-28.
131. Xue M, Yin HJ, Wu CF, et al. Effect of Chinese drugs for activating blood circulation and detoxifying on indices of thrombosis inflammatory reaction and tissue damage in a rabbit model of toxinheat and blood stasis syndrome. Chin J Integr Med 2013; 19: 42- 47.
132. Lei Y, Gao Q, Chen KJ. Effects of extracts from Panax notoginseng and Panax ginseng fruit on vascular endothelial cell proliferation and migration in vitro. Chin J Integr Med 2008; 14: 37-41.
133. Jiang YR, Miao Y, Yang L, et al. Effect of Chinese herbal drugcontaining serum for activating-blood and dispelling-toxin on ox- LDL-induced inflammatory factors' expression in endothelial cells. Chin J Integr Med 2012; 18: 30-33.
134. Huang Y, Yin HJ, Ma XJ, et al. Correlation between Fc γ R III a and aortic atherosclerotic plaque destabilization in ApoE knockout mice and intervention effects of effective components of Chuanxiong Rhizome and Red Peony Root. Chin J Integr Med 2011; 17: 355-60.
135. Xue M, Zhang L, Yang L, et al. Effect of Chinese herbal medicine for activating blood circulation and detoxifying on expression of inflammatory reaction and tissue damage related factors in experimental carotid artery thrombosis rats. Chin J Integr Med 2010; 16: 247-51.
136. Ma XJ, Yin HJ, Chen KJ. Appraisal of the prognosis in patients with acute myocardial infarction treated with primary percutaneous coronary intervention. Chin J Integr Med 2009; 15: 236-40.
137. Wu T, Ni J, Wei J. Danshen (Chinese medicinal herb) preparations for acute myocardial infarction. Cochrane Database Syst Revi 2008; 2: Art. No.: CD004465. DOI: 10.1002/14651858.CD004465. pub2.
138. Duan WH, Lu F, Li LZ, et al. Clinical efficacy of traditional Chinese medicine on acute myocardial infarction--a prospective cohort study. Chin J Integr Med 2012; 18: 399-405.
139. Zhou YC, Liu B, Li YJ, et al. Effects of Buyang Huanwu Decoction on ventricular remodeling and differential protein profile in a rat model of myocardial infarction. Evid Based Complement Alternat Med 2012; 2012: Article ID 385247.
140. Xie M, Wang TS, Wu DL, Zhao RH. Cardioprotective effect of the Compound Yangshen Granule in rat models with acute myocardial infarction. Evid Based Complement Alternat Med 2012; 2012: Article ID 717123.
141. Fu CG, Gao ZY, Wang PL, et al. Study on the diagnostic criteria for coronary heart disease patients of blood stasis syndrome. Zhongguo Zhong Xi Yi Jie He Za Zhi 2012; 32: 1285-6.
142. Xu H, Lu XY, Chen KJ, Shi DZ. Study on correlation of bloodstasis syndrome and its accompanied syndromes with pathological changes showed in coronary angiography and restenosis after percutaneous coronary intervention. Zhongguo Zhong Xi Yi Jie He Za Zhi 2007; 27: 8-13.
143. Du JP, Shi DZ, Li TC, Xu H, Chen H. Correlation between blood stasis syndrome and pathological characteristics of coronary artery in patients with coronary heart disease. J Chin Integr Med 2010; 8: 848-52.
144. Jiang WY. Therapeutic wisdom in traditional Chinese medicine: a perspective from modern science. Trends Pharmacol Sci 2005; 26: 557-63.
145. Feng Y, Xu H, Qu D, Zheng F, Shi DZ, Chen KJ. Study on the tongue manifestations for the blood-stasis and toxin syndrome in the stable patients of coronary heart disease. Chin J Integr Med 2011; 17: 333-8.
146. Cho KH, Kim KP, Woo BC, et al. Relationship between blood stasis syndrome score and cardioankle vascular index in stroke patients. Evid Based Complement Alternat Med 2012; 2012: Article ID 696983.
147. Xu H, Shi DZ, Chen KJ. Atherosclerosis: an integrative east-west medicine perspective. Evid Based Complement Alternat Med 2012; 2012: Article ID 148413.
148. Liu Y, Lin R, Shi XL, et al. The roles of Buyang Huanwu Decoction in anti-inflammation, antioxidation and regulation of lipid metabolism in rats with myocardial ischemia. Evid Based Complement Alternat Med 2011; 2011: Article ID 561396.
149. Sun S, Xu H, Ngeh L. The evaluation of Chinese therapeutic food for the treatment of moderate dyslipidemia. Evid Based Complement Alternat Med2012; 2012: Article ID 508683.
150. Xie WD, Zhao YN, Zhang YO. Traditional Chinese medicines in treatment of patients with type 2 diabetes mellitus. Evid Based Complement Alternat Med 2011; 2011: Article ID 726723.
151. Fu CH, Yu LH, Zou YH, et al. Efficacy of Chuanxiong Ding Tong Herbal Formula Granule in the treatment and prophylactic of migraine patients: a randomized, double-blind, multicenter, placebo controlled trial. Evid Based Complement Alternat Med 2012; 2012: Article ID 967968.
152. Sun SJ, Dai JY, Wang WY, et al. Metabonomic evaluation of ZHENG differentiation and treatment by Fuzhenghuayu Tablet in hepatitis-B-caused cirrhosis. Evid Based Complement Alternat Med 2012; 2012: Article ID 453503.
153. Chang PJ, Lin CC, Chen YC, et al. Use of herbal dietary supplement Si-Wu-Tang and health-related quality of life in postpartum women: a population-based correlational study. Evid Based Complement Alternat Med 2013; 2013: Article ID 790474.
154. Fang RC, Tsai YT, Lai JN, Yeh CH, Wu CT. The traditional Chinese medicine prescription pattern of endometriosis patients in Taiwan: a population-based study. Evid Based Complement Alternat Med 2012; 2012: Article ID 591391.
155. Lu P, Chen JX, Zhao HH, et al. In silico syndrome prediction for coronary artery disease in traditional Chinese medicine. Evid Based Complement Alternat Med 2012; 2012: Article ID 142584.
156. Li O, Xu H. The occurrence of cardiovascular events of coronary heart disease inpatients and study on Chinese medicine syndrome distribution laws. Zhongguo Zhong Xi Yi Jie He Za Zhi 2012; 32: 603-6.
157. Chinese Association of Integrative Medicine, Professional Committee of Blood Circulation. Diagnostic criteria of blood stasis. Zhong Xi Yi Jie He Za Zhi 1987; 7: Cover 2.
158. Wang J, Chen KJ, Weng WL, et al. Research on diagnostic criteria of blood-stasis symptom-complex. Zhong Xi Yi Jie He Za Zhi 1988; 10: 585-7, 9.
159. Wang J, Chen KJ, Weng WL. Computerized stepwise regression for blood stasis symptom-complex in coronary heart diseases. Zhong Xi Yi Jie He Za Zhi 1991; 11: 47-9.
160. Society of Cardiology and Chinese Association of the Integration of Traditional and Western Medicine. The diagnostic criteria of TCM in coronary heart disease. Zhong Xi Yi Jie He Za Zhi 1991; 11: 257.
161. Matsumoto C, Kojima T, Ogawa K, et al. A proteomic approach for the diagnosis of "Oketsu" (blood stasis), a pathophysiologic concept of Japanese traditional (Kampo) medicine. Evid Based Complement Alternat Med 2008; 5: 463-74.
162. Cooper EL. eCAM: integrative genomics and fecundity. Evid Based Complement Alternat Med 2009; 6: 129-31.
163. Li XF, Jiang YR, Gao ZY, Yin HJ, Chen KJ. Screening, identification and analysis of platelet differential functional proteins in patients with coronary heart disease of blood-stasis pattern. Zhongguo Zhong Xi Yi Jie He Za Zhi 2010; 30: 467-73.
164. Ma XJ, Yin HJ, Chen KJ. Research progress of correlation between blood-stasis syndrome and inflammation. Zhongguo Zhong Xi Yi Jie He Za Zhi 2007; 27: 669-72.
165. Ma XJ, Yin HJ, Chen KJ. Investigation of gene expression profiles in patients with blood stasis syndrome. J Chin Integr Med 2008; 6: 355-60.
166. Chen KJ, Xue M, Yin HJ. The relationship between platelet activation and coronary heart disease and blood-stasis syndrome. Shou Du Yi Ke Da Xue Xue Bao 2008; 29: 266-9.
167. Zhao HH, Chen JX, Shi Q, et al. Metabolomics-based study of clinical and animal plasma samples in coronary heart disease with blood stasis syndrome. Evid-Based Complement Alternat Med 2012; 2012: Article ID 638723.
168. Xue M, Chen KJ, Yin HJ. Relationship between platelet activation related factors and polymorphism of related genes in patients with coronary heart disease of blood-stasis syndrome. Chin J Integr Med 2008; 14: 267-73.
169. Liu Y, Yin HJ, Chen KJ. Research on the correlation between platelet gelsolin and blood-stasis syndrome of coronary heart disease. Chin J Integr Med 2011; 17: 587-92.
170. Feng PF, Qin NP, Qin YG, Cheng ZG, Feng JX. Effect of Composite Salviae Dropping Pill on endothelin gene expression in circulating endothelial cells of patients with coronary heart disease. Zhongguo Zhong Xi Yi Jie He Za Zhi 1999; 19: 286-8.
171. Zhang L, Liu Y, Lu XT, et al. Traditional Chinese medication Tongxinluo dose-dependently enhances stability of vulnerable plaques: a comparison with a high-dose simvastatin therapy. Am J Physiol Heart Circ Physiol 2009; 297: H2004-14.
172. Cheng YT, Yang YJ, Zhang HT, et al. Pretreatment with Tongxinluo protects porcine myocardium from ischaemia / reperfusion injury through a nitric oxide related mechanism. Chin Med J 2009; 122: 1529-38.
173. Song J, Chen WY, Wu LY, et al. A microarray analysis of angiogenesis modulation effect of Xuefu Zhuyu Decoction on endothelial cells. Chin J Integr Med 2012; 18: 502-6.
174. Gao D, Wu Ly, Jiao YH, et al. The effect of Xuefu Zhuyu Decoction on in vitro endothelial progenitor cell tube formation. Chin J Integr Med 2010; 16: 50.
175. Li CS, Qu ZQ, Wang SS, et al. Effects of Suxiao Jiuxin Pill on oxidative stress and inflammatory response in rats with experimental atherosclerosis. J Trad Chine Med 2011; 31: 107-11.
176. Ge YX, Duan YY, Ruan LT, Cao TS, Lv FQ, Zhou XY. Protective effect of the compound danshen diwan on endothelium function of blood vessel. Zhongguo Lin Chuang Kang Fu 2004; 8: 1096-7.
177. Zhao MZ, Wang JR, Wei JP, Gao CM, Zhang YY. The effects of Dan shen pills on myocyte apoptosis and the expression of apoptosis- associated genes in rat hearts with myocardial ischemia and reperfusion. Zhongguo Lin Chuang Yao Li Xue Za Zhi 1999; 15: 288-91.
178. Wang J, Xiong XJ, Zhang LF. The disease-syndrome combination mode and exploration on its clinical application. Zhongguo Zhong Xi Yi Jie He Za Zhi 2012; 32: 297-9.
179. Xiong XJ. Study on the history of formulas corresponding to syndromes. J Chin Integr Med 2010; 8: 581-8.
180. Chen KJ, Xie YH, Liu Y. Profiles of traditional Chinese medicine schools. Chin J Integr Med 2012; 18: 534-8.
181. Cheung F. TCM: made in China. Nature 2011; 480: S82-3.
182. Tian P. Where west meets east. Nature 2011; 480: S84-6.
183. Zhang JH, Shang HC, Gao XM, et al. Methodology and reporting quality of systematic review/meta-analysis of traditional Chinese medicine. J Altern Complement Med 2007; 13: 797-805.
184. Manheimer E, Wieland S, Kimbrough E, Cheng K, Berman BM. Evidence from the Cochrane Collaboration for traditional Chinese medicine therapies. J Altern Complement Med 2009; 15: 1001-14.
185. Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Groups. Preferred Reporting Items for Systematic Reviews and Meta-analyses: The PRISMA statement. PLOS Med 2009; 6: article e1000097.
186. Qiu Y, Xu H, Shi DZ. Traditional Chinese herbal products for coronary heart disease: an overview of cochrane reviews. Evid- Based Complement Alternat Med 2012; 2012: Article ID 417387.
187. Luo J, Xu H. Outcome measures of Chinese herbal medicine for coronary heart disease: an overview of systematic reviews. Evid- Based Complement Alternat Med 2012; 2012: Article ID 927392.
188. Jeanne LS. Applying evidence-based medicine to traditional Chinese medicine: debate and strategy. J Altern Complement Med 2006; 12: 255-63.